Skip to main content
. 2019 Oct 15;19:90. doi: 10.1186/s12894-019-0530-0

Table 2.

Recurrence, progression and treatment failure rates of the two groups

Gemcitabine Epirubicin or Pirarubicin P
Recurrence
 Yes 7 (8.33%) 18 (45%) 0.000
 No 77 (91.67%) 22 (55%)
Progression
 Yes 2 (2.38%) 8 (20%) 0.001
 No 82 (97.62%) 32 (80%)
Treatment failure
 Yes 7 (8.33%) 10 (25%) 0.012
 No 77 (91.67%) 30 (75%)